Monday Apr 7
LipoScience Reaches New 52-Week Low at $2.95
LipoScience shares reached a new 52-week low on Monday , Analyst Ratings News reports.
Applied Clinical Trials
Patients Managed to Target LDL Particle Number Experience Fewer...
Data demonstrates that the NMR LipoProfile test provides clinically reliable information to help reduce cardiovascular events, especially in patients with diabetes and those on statin therapy Data demonstrates that the NMR LipoProfile test provides clinically reliable information to help reduce cardiovascular events, especially in patients with ... (more)
Why LipoScience (LPDX) Stock Hit a One-Year Low Today
The company reduced its guidance to $11.8 million from $12.2 million, which is less than the Capital IQ consensus estimate of $12.24 million.
LipoScience terminates diagnostic contract after customer begins offering a similar test
Raleigh diagnostics company LipoScience , Inc. terminated its relationship with Health Diagnostics Laboratory, Inc, one of its laboratory customers, after HDL began offering its own version of roughly the same test LipoScience manufactures.
Deep Value In This Diagnostic Company Might Attract Activists
Despite 2013 being one of the best years for IPO's in recent memory, shares of Liposcience , which went public at $9, quickly rose to $11 only to plummet to $4 by the end of the year.